Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ergocalciferol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | TST | Q16762 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | PGR | P06401 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ergocalciferol SCHEMBL13693869 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL222899 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL13526523 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL12464764 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL24855744 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL14404820 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL24565106 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL19386228 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL3422 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL20510995 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202802-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | EXELTIS USA, INC. | 2017-07-20 | — | — | US | claimed |
| US-20170112178-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | Chemo S.A. France (FR) | 2017-04-27 | — | — | US | claimed |
| US-20130011377-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | Chemo S.A. France (FR) | 2013-01-10 | — | — | US | claimed |
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-08-28 | — | — | US | claimed |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-05 | — | — | US | claimed |
| US-20060018937-A1 | Steroid kit and foamable composition and uses thereof | FOAMIX LTD. | 2006-01-26 | — | — | US | claimed |
| US-20240082197-A1 | DELIVERY METHODS FOR OMEGA-3'S AND COMPOSITIONS FOR VITAMINS AND MINERALS USED TO ENHANCE VISUAL ACUITY AND MENTAL DEVELOPMENT IN THE HUMAN BODY | VIVA LIFE SCIENCE INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20210315852-A1 | DELIVERY METHODS FOR OMEGA-3'S AND COMPOSITIONS FOR VITAMINS AND MINERALS USED TO ENHANCE VISUAL ACUITY AND MENTAL DEVELOPMENT IN THE HUMAN BODY | VIVA LIFE SCIENCE, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210196631-A1 | CONTAINER SYSTEM AND PHARMACEUTICAL FOAM COMPOSITION COMPRISING BETAMETHASONE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2021-07-01 | — | — | US | disclosed |
| US-20210128459-A1 | GUMMY COMPOSITIONS FOR NUTRITIONAL SUPPLEMENTATION | EXELTIS USA, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-10905650-B2 | Gummy compositions for nutritional supplementation | EXELTIS USA, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190307887-A1 | Body Cavity Foams | VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2019-10-10 | — | — | US | disclosed |
| US-20190021385-A1 | ORALLY DISSOLVABLE COMPOSITIONS FOR NUTRITION SUPPLEMENTATION | EXELTIS USA, INC. | 2019-01-24 | — | — | US | disclosed |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | FOAMIX LTD. (IL) | 2008-08-28 | — | — | US | disclosed |
| US-20080069779-A1 | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof | FOAMIX LTD. (IL) | 2008-03-20 | — | — | US | disclosed |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD | 2008-03-13 | — | — | US | disclosed |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-05 | — | — | US | disclosed |
| US-20060275218-A1 | Foamable vehicle and pharmaceutical compositions thereof | FOAMIX LTD. (IL) | 2006-12-07 | — | — | US | disclosed |
| US-20060018937-A1 | Steroid kit and foamable composition and uses thereof | FOAMIX LTD. | 2006-01-26 | — | — | US | disclosed |
| US-20050271598-A1 | Body cavity foams | FOAMIX LTD. | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050271598-A1 | Body cavity foams | FABP4, FFAR1, FFAR2 | VDR 754/4885ALDH1A1 456/4885ALOX15 24/4885 |
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | NR5A1, CYP17A1, LIPA | VDR 547/4885ALDH1A1 1705/4885ALOX15 232/4885 |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | CUTA, SLTM, SMO | VDR 3447/4885ALDH1A1 3777/4885ALOX15 420/4885 |
| US-20210196631-A1 | CONTAINER SYSTEM AND PHARMACEUTICAL FOAM COMPOSITION COMPRISING BETAMETHASONE | CYP24A1, CYP2R1, VDR | VDR 3/4885ALDH1A1 1272/4885ALOX15 813/4885 |
| US-20080069779-A1 | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof | PROC, VKORC1, TTPA | VDR 7/4885ALDH1A1 1101/4885ALOX15 273/4885 |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | PSEN2, APP, PSEN1 | VDR 90/4885ALDH1A1 3514/4885ALOX15 2047/4885 |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | VDR 3807/4885ALDH1A1 2577/4885ALOX15 76/4885 |
| US-20190307887-A1 | Body Cavity Foams | FABP4, FFAR1, FFAR2 | VDR 754/4885ALDH1A1 456/4885ALOX15 24/4885 |
| US-20060018937-A1 | Steroid kit and foamable composition and uses thereof | KIT, GK, HSD17B7 | VDR 871/4885ALDH1A1 246/4885ALOX15 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.